Skip to main content
International Journal of Genomics logoLink to International Journal of Genomics
. 2023 Dec 22;2023:5583231. doi: 10.1155/2023/5583231

Transcription Analysis of the THBS2 Gene through Regulation by Potential Noncoding Diagnostic Biomarkers and Oncogenes of Gastric Cancer in the ECM-Receptor Interaction Signaling Pathway: Integrated System Biology and Experimental Investigation

Ali Barani 1,2, Kamyar Beikverdi 1,3, Benyamin Mashhadi 1,4, Naeimeh Parsapour 1,5, Mohammad Rezaei 1,6, Pegah Javid 1,7, Mansoureh Azadeh 1,
PMCID: PMC10756743  PMID: 38162289

Abstract

Background

Gastric cancer (GC) is the second most frequent cause of cancer-related death worldwide and the fourth most common malignancy. Despite significant improvements in patient survival over the past few decades, the prognosis for patients with GC remains dismal because of the high recurrence rate. In this comprehensive system biology and experimental investigation, we aimed to find new novel diagnostic biomarkers of GC through a regulatory RNA interaction network.

Methods

Gene expression, coexpression, and survival analyses were performed using microarray and RNAseq datasets (analyzed by RStudio, GEPIA2, and ENCORI). RNA interaction analysis was performed using miRWalk and ENCORI online databases. Gene set enrichment analysis (GSEA) was performed to find related signaling pathways of up- and downregulated genes in the microarray dataset. Gene ontology and pathway enrichment analysis were performed by the enrichr database. Protein interaction analysis was performed by STRING online database. Validation of expression and coexpression analyses was performed using a qRT-PCR experiment.

Results

Based on bioinformatics analyses, THBS2 (FC: 7.14, FDR < 0.0001) has a significantly high expression in GC samples. lncRNAs BAIAP2-AS1, TSIX, and LINC01215 have RNA interaction with THBS2. BAIAP2-AS1 (FC: 1.44, FDR: 0.018), TSIX (FC: 1.34, FDR: 0.038), and LINC01215 (FC: 1.19, FDR: 0.046) have significant upregulation in GC samples. THBS2 has a significant role in the regulation of the ECM-receptor signaling pathway. miR-4677-5p has a significant RNA interaction with THBS2. The expression level of THBS2, BAIAP2-AS1, TSIX, and LINC01215 has a nonsignificant negative correlation with the survival rate of GC patients (HR: 0.28, logrank p: 0.28). qRT-PCR experiment validates mentioned bioinformatics expression analyses. BAIAP2-AS1 (AUC: 0.7136, p value: 0.0096), TSIX (AUC: 0.7456, p value: 0.0029), and LINC01215 (AUC: 0.7872, p value: 0.0005) could be acceptable diagnostic biomarkers of GC.

Conclusion

BAIAP2-AS1, lncRNA LINC01215, lncRNA TSIX, and miR-4677-5p might modulate the ECM-receptor signaling pathway via regulation of THBS2 expression level, as the high-expressed noncoding RNAs in GC. Furthermore, mentioned lncRNAs could be considered potential diagnostic biomarkers of GC.

1. Introduction

Globally, gastric cancer (GC) is the second most common cause of cancer-related mortality and the fourth most prevalent malignant disease [1]. The prognosis for patients with GC is still poor because of the high recurrence rate, despite major advancements in patient survival over the past several decades [2]. GC is frequently identified at an advanced stage. Since most cases of GC are asymptomatic until they reach late stages, it is crucial to use efficient screening techniques to identify cases early in order to reduce GC fatalities [2]. In order to serve as a marker for healthy biologic processes, destructive processes, or pharmacological responses to therapeutic interventions, biomarkers are traits that can be objectively studied and measured. Recent developments in genome analysis have led to the discovery of several biomarkers relating to DNA, RNA, exosomes, etc. The creation of these biomarkers in the field of cancer therapy is anticipated to have a significant impact on the progression of the disease, the choice of effective therapeutic approaches, and effective follow-up programs [2].

Better technology and bioinformatics analyses to comprehend dynamic changes in biology and tumor plasticity will be linked to further advancements in cancer therapy. Consideration must be given to tumor heterogeneity, the interaction between the cancer genome and the epigenome, the surrounding microenvironment, and vertical access (changes over time) of cancer biological components to address molecular evolution and horizontal access (changes over sites of disease involvement) to address tumor heterogeneity. The potential of computational medicine and data sharing inspires researchers to create exciting initiatives that integrate big data and bioinformatics. The possibility of treating cancer ultimately rests with the development of efficient treatment approaches, well-planned clinical trials, and coordinated efforts among crucial players in cancer therapy [3].

Long noncoding RNAs (lncRNAs) have gotten a lot of attention as possible diagnostic, prognostic, or predictive biomarkers because of their high specificity and ease of accessibility in a noninvasive way, as well as their aberrant expression under diverse pathological and physiological situations. They could possibly be used as stomach cancer treatment targets [4].

Based on previous studies, lncRNAs have significant roles in the different biological processes correlated to GC. For example, lncRNA PCAT-1, which is significantly expressed in tissues and cells of gastric cancer resistant to DDP, increases DDP resistance in gastric cancer cells by engaging EZH2 to epigenetically repress PTEN expression and controlling the miR-128/ZEB1 axis [5, 6]. EZH2 is also considered as a potential prognostic biomarker of hepatocellular carcinoma [7]. Similarly, it has been discovered that the DDP-resistant gastric cancer cells SGC7901/DDP and BGC823/DDP express the lncRNA DANCR at a high level. DANCR knockdown in these cells encourages apoptosis and prevents cell division. On the other hand, DDP-induced SGC901 and BGC823 cells with overexpressed DANCR might increase the expression of MDR genes MDR1 and MRP1 [8]. Through the upregulation of MDR1, MRP1, and Bax expression as well as the downregulation of Bcl-2 expression, lncRNA SNHG5 decreased the DDP sensitivity of the gastric cancer cells BGC823 and SGC7901 [9].

Based on GeneCards (http://genecards.org), THBS2 produces a member of the thrombospondin family of proteins. It is a homotrimeric glycoprotein with disulfide links that mediate interactions between cells and between cells and a matrix. It has been demonstrated that this protein acts as a powerful inhibitor of tumor angiogenesis and proliferation. Studies of the mouse equivalent imply that this protein may modify the mesenchymal cells' cell surface characteristics and be involved in cell adhesion and migration. Through regulation by miR-221-3p, THBS2 might promote angiogenesis in cervical cancer [10]. Zhang et al. in 2022 revealed that THBS2 has a significant upregulation in gastric cancer patients. Also, this study revealed that high expression of THBS2 has significant correlations with pathological grade, T stage, and poor overall survival of patients [11].

In this study, we performed a comprehensive bioinformatics investigation and experimental validation to find potential novel biomarkers of GC. Also, we demonstrate novel RNA and protein interaction networks to find novel regulatory noncoding RNAs in GC patients. The central core of this study is the THBS2 gene as a potential misregulated mRNA in GC patients.

2. Materials and Methods

2.1. Microarray Data Analysis

Microarray analysis was performed on the gastric cancer-related datasets. GSE54129 was investigated in order to find the differentially expressed genes (DEGs) in the gastric cancer microarray datasets. 111 GC samples and 21 control samples from this dataset were evaluated. GPL570 (HG-U133 Plus 2, Affymetrix Human Genome U133 Plus 2.0 Array) is the source of this dataset. The raw data from the GEO online database (https://www.ncbi.nlm.nih.gov/geo/) was transmitted to the RStudio environment and then normalized using the affy [12] package. The microarray dataset underwent statistical analysis using the limma [13] package. The affy and limma packages were obtained from the Bioconductor online site (https://www.bioconductor.org/). For the analysis of microarray data, a significance threshold of 0.0001 was chosen (adjusted p value). The microarray data analysis visualizations were created using the ggplot2 [14] and pheatmap packages, which are available from CRAN (https://cran.r-project.org). In this microarray study, the expression of 47568 RNA transcript (21257 genes) was investigated. Following normalization (RMA method), logarithmic scaling, and elimination of the transcripts with no expression in the dataset, the difference in the expression level of all RNAs was calculated. The RNAs with logFC > 3 were chosen as the upregulated RNAs, while logFC < −3 was selected as the threshold of low expression.

2.2. Gene Set Enrichment Analysis (GSEA)

The samples in the GSE54129 dataset were split into control and tumor samples. Gene set enrichment analysis (GSEA) (https://software.broadinstitute.org/gsea/) was used to investigate related signaling pathways [15]. p < 0.05 was used to assess what words were significant.

2.3. Gene Ontology (GO), Expression, Survival, and RNA Interaction Analyses

ENCORI online database carried out the mRNA-lncRNA interaction analyses (https://starbase.sysu.edu.cn/) [16]. The online software GEPIA2 [17] (http://gepia2.cancer-pku.cn/) and ENCORI carried out expression, correlation, and survival analyses. Using Cytoscape software (version 3.8.2), RNA interactions were visualized [18, 19]. The STRING online database analyzed and visualized protein-protein interactions [20]. GO and pathway enrichment analyses were performed by enrichr online database [2123]. The investigation of the interactions between microRNAs and mRNAs was carried out by miRWalk (http://mirwalk.umm.uni-heidelberg.de/) [2426]. The top miRNAs with the following criteria were selected: binding probability, 1; position, 3′UTR (seed region); and lowest binding energy. Sampe size was calculated using the following formula: n = ((σA2 + σB2)(Z1−α/2 + Z1−β)2)/δ2. σA2 + σB2 is the variance of control and tumor samples, and Z1−α/2 and Z1−β are the statistical power of samples (numeric values: 1.96 and 0.84, respectively).

2.4. Clinical Characteristics of Tissue Samples

All patients signed written consent forms, and all methods for the research in this study involving human samples were approved by the Al-Zahra Hospital Ethics Committee, Isfahan University of Medical Science. Samples of normal gastric tissue and gastric cancer from 25 individuals with gastric cancer were compared in a case-control study. Normal gastric tissues are adjacent to tumor samples. None of the patients had ever received radiation or chemotherapy. Tissue samples were rinsed in distilled water and promptly frozen in liquid nitrogen for RNA Later solution (Invitrogen, USA) immersion for pathologist assessment. The clinicopathological characteristics of patients with breast and stomach cancer are listed in Table 1.

Table 1.

Clinicopathological analysis of gastric cancer samples.

Variable Status Number %
Age <50 8 32
>50 17 68

Sex Male 18 72
Female 7 28

Tumor size <5 cm 10 40
>5 cm 15 60

Histology Adenocarcinoma 23 92
Mucinous adenocarcinoma 1 4
Signet ring carcinoma 1 4

Perineural invasion No 6 24
Yes 19 76

Nodal extension No 21 84
Yes 4 16

TNM staging I 1 4
II 6 24
IIIA 2 8
IIIB 4 16
IV 12 48

Family history No 19 76
Yes 6 24

Smoking DX-smoker at diagnosis but discontinued 2 8
Ex-smoker 2 8
Nonsmoker 20 80
smoker 1 4

2.5. RNA Extraction, cDNA Synthesis, and qRT-PCR Experiment

TRIzol was employed to extract the RNA from both tumorous and normal tissues (Invitrogen, Carlsbad, CA, USA). Following the RNA extraction steps, cDNA synthesis was performed using the TaKaRa cDNA synthesis kit according to the manufacturer's instructions (TaKaRa, Tokyo, Japan). SYBR green, an Amplicon Company product from Denmark, was utilized to do real-time PCR, and a MIC real-time PCR instrument was used to perform reverse transcription quantitative polymerase chain reaction (RT-qPCR) experiment. Following conducting, the following parameters for the PCR reactions were set: initial denaturation, 95°C for 15 minutes; secondary, 95°C for 15 seconds; 60°C for 20 seconds; and 72°C for 20 seconds. There were 40 cycles in total. The sequences of the primers, which were created by TAQ Copenhagen Company (Denmark), are displayed in Table 1. As an internal control, the related expression was normalized using the quantity of GAPDH. In Table 2, the primer sequence is displayed.

Table 2.

Table of primer sequence.

Gene 5′-->3 Forward/reverse
THBS2 CGTGGACAATGACCTTGTTG F
GCCATCGTTGTCATCATCAG R

BAIAP2-AS1 ACCAGAAAGTTCCAGAGCGG F
ACCATGCGGATAGCTTCACC R

TSIX GTGATCCTCACAGGACTGCAACA F
AGCTGAGTCTTCAGCAGGTCCAA R

LINC01215 AGCGCTTACCACTGTCCATT F
TGCCCAGGTGAACTGTTTTCT R

GAPDH AGCCACATCGCTCAGACAC F
GCCCAATACGACCAAATCC R

The GraphPad Prism application was used to statistically evaluate the real-time PCR data and related visualizations (version 8). The qRT-PCR data were compared using the CT method to determine the expression levels between the tumor and control samples [27]. The Shapiro-Wilk test was used to the expression data in order to ascertain whether the data were normal. Using paired t-test and Wilcoxon test on the CT data, the expression levels in tumor and control samples were compared. The DEG analysis of the microarray data was performed in RStudio (4.1.2). Based on sensitivity and specificity, the recipient operating characteristic (ROC) analysis was carried out by the GraphPad Prism for the real-time PCR datasets. A p value of less than 0.05 was selected as the significance threshold for this study. AUC values between 0.7 and 0.8 in the ROC analysis are regarded as acceptable, 0.8 and 0.9 as good (signifying a good biomarker), and 0.9 and 1 as excellent (indicating an outstanding biomarker).

3. Results

3.1. Microarray Data Analysis

Microarray data analysis revealed 37 upregulated genes and 60 low-expressed genes in the GSE54129 dataset. List of top 20 up- and downregulated genes is provided in Table 3. Figure 1 shows the heatmap of top 50 DEGs. Correlation clustering method was performed on samples and genes in this heatmap. Control and tumor samples are completely separated in different clusters. Also, upregulated and downregulated genes are completely clustered. Volcano plot of all genes in GSE54129 revealed up- and downregulated genes in the dataset (Figure 2).

Table 3.

List of top 20 upregulated and downregulated genes in GSE54129.

ID logFC AveExpr p value Adj. p value Gene symbol Down/up
220191_at -5.96862787 9.308647992 3.84E‐09 1.61E‐08 GKN1 Down
238222_at -5.882742555 9.145683068 1.24E‐10 6.32E‐10 GKN2 Down
208138_at -5.451885409 6.962448568 1.26E‐23 3.58E‐22 GAST Down
205979_at -5.275111089 5.955695606 4.36E‐23 1.15E‐21 SCGB2A1 Down
213921_at -5.271075203 7.443574371 2.61E‐15 2.43E‐14 SST Down
231646_at -5.100492447 7.808510962 2.43E‐14 2.00E‐13 DPCR1 Down
210065_s_at -4.868614646 7.11555797 3.38E‐22 7.86E‐21 UPK1B Down
213953_at -4.865974875 8.113243682 3.58E‐11 1.97E‐10 KRT20 Down
221122_at -4.85342997 6.729619568 3.70E‐24 1.13E‐22 HRASLS2 Down
241137_at -4.717247165 7.873223023 1.58E‐13 1.17E‐12 DPCR1 Down
243764_at -4.688944304 8.296975061 2.35E‐12 1.49E‐11 VSIG1 Down
204260_at -4.65753578 5.269594917 6.42E‐25 2.18E‐23 CHGB Down
207033_at -4.657105699 6.371562909 2.44E‐09 1.06E‐08 GIF Down
234780_at -4.632035685 4.37024875 2.54E‐51 2.28E‐48 Down
207249_s_at -4.5518883 6.956546129 6.48E‐17 7.49E‐16 SLC28A2 Down
214046_at -4.478426687 5.933183333 3.66E‐14 2.94E‐13 FUT9 Down
234632_x_at -4.460705311 5.982485447 2.22E‐20 4.07E‐19 Down
210641_at -4.440274593 6.507433205 1.54E‐25 5.58E‐24 CAPN9 Down
227306_at -4.421510073 6.865494508 3.82E‐24 1.17E‐22 RP11-363E7.4 Down
214385_s_at -4.329929907 8.909946864 6.51E‐11 3.46E‐10 MUC5AC Down
209875_s_at 4.055061344 8.400801758 3.12E‐15 2.87E‐14 SPP1 Up
210764_s_at 4.074797407 8.451531992 1.01E‐30 7.06E‐29 CYR61 Up
203649_s_at 4.079081377 8.611325803 4.83E‐16 4.96E‐15 PLA2G2A Up
209156_s_at 4.11512948 9.774724742 1.31E‐33 1.31E‐31 COL6A2 Up
202859_x_at 4.117296435 8.163282288 3.98E‐15 3.62E‐14 CXCL8 Up
218469_at 4.168860215 9.899021644 2.25E‐21 4.68E‐20 GREM1 Up
224646_x_at 4.199296712 7.476765447 1.15E‐15 1.12E‐14 H19 Up
204051_s_at 4.252115166 7.362223727 1.71E‐18 2.45E‐17 SFRP4 Up
202310_s_at 4.300071432 11.33718549 9.54E‐36 1.28E‐33 COL1A1 Up
201289_at 4.344681412 9.535824144 9.94E‐36 1.33E‐33 CYR61 Up
1555229_a_at 4.398480865 8.495294055 5.14E‐39 1.15E‐36 C1S Up
209395_at 4.412985552 7.207506621 4.45E‐17 5.27E‐16 CHI3L1 Up
223121_s_at 4.462926494 8.277239652 1.74E‐19 2.83E‐18 SFRP2 Up
201058_s_at 4.469669609 10.22080471 1.82E‐24 5.81E‐23 MYL9 Up
218468_s_at 4.580281615 9.473598068 6.43E‐24 1.90E‐22 GREM1 Up
227140_at 4.681301515 7.462719811 8.61E‐27 3.71E‐25 INHBA Up
226237_at 4.766250328 7.943784326 2.30E‐26 9.38E‐25 COL8A1 Up
238320_at 4.893182068 8.962860189 5.35E‐50 4.31E‐47 MIR612 Up
223122_s_at 5.876935726 9.798533583 1.31E‐26 5.49E‐25 SFRP2 Up
227404_s_at 5.901635278 10.46172328 3.38E‐60 8.45E‐57 EGR1 Up

Figure 1.

Figure 1

Heatmap of top 50 differentially expressed genes in GSE54129. Genes are categorized into different clusters, based on the expression level. Samples also are categorized into two main clusters based on group (control or tumor). The first 21 columns in the left side of heatmap represent normal samples and other 111 columns in the right side of heatmap are showing the tumor samples.

Figure 2.

Figure 2

Volcano plot showing the DEGs in the GSE54129. Red color indicates the upregulated genes and green color indicates the downregulated genes. THBS2 is indicated by a black point in the plot as a significantly upregulated gene. Further analyses were performed on THBS2 as a significant high-expressed mRNA.

3.2. GSEA

Based on GSEA, upregulated genes of GSE54129 regulate the ECM-receptor interaction signaling pathway (Figures 3 and 4). Based on mentioned analysis, THBS2 is the most significant upregulated gene in the ECM-receptor interaction pathway (FWER p value < 0.0001, rank metric score: 1.38). THBS2 was selected for further investigation. List of significant upregulated genes in mentioned signaling pathway is provided in Table 4.

Figure 3.

Figure 3

Profile of the running ES score and positions of gene set members on the rank ordered list. Area under the yellow plot indicates the significance level of pathway analysis. Each gene in the ECM-receptor pathway is shown in the plot by a bar line. Genes with higher expression change are located in the left side on the plot. The first gene (the most significant dysregulated gene) is the THBS2 that is located at the left side with higher score.

Figure 4.

Figure 4

Heatmap of upregulated genes, involved in ECM-receptor signaling pathway. Yellow color indicates normal samples, and the gray color indicates tumor samples. Red color indicates higher expression level of genes in related sample, and the blue color indicates lower expression level. THBS2 has the most change in the expression level, as a significant high-expressed gene in the GC samples.

Table 4.

List of significant upregulated genes in the ECM-receptor interaction pathway.

Symbol Rank in gene list Rank metric score Running ES
THBS2 13 1.38 0.0489
SPP1 17 1.317 0.0962
COL6A2 28 1.222 0.1396
ITGA5 54 1.079 0.1771
THBS4 62 1.045 0.2143
THBS1 130 0.86 0.2417
COMP 166 0.811 0.269
COL11A1 204 0.764 0.2945
ITGA7 212 0.753 0.3212
FN1 224 0.739 0.3472
TNC 256 0.703 0.3709
COL4A4 315 0.663 0.3917
COL6A3 367 0.629 0.4116
COL4A1 561 0.537 0.4208
COL1A2 741 0.481 0.4287
ITGA11 751 0.479 0.4455
COL5A3 765 0.476 0.4619
COL4A2 842 0.457 0.4743
COL5A1 863 0.451 0.4895
VWF 907 0.443 0.5032
SV2A 909 0.443 0.5191
COL5A2 1021 0.421 0.5284
LAMA5 1058 0.414 0.5414
SDC3 1162 0.396 0.5502
COL6A1 1174 0.393 0.5638
LAMA4 1290 0.374 0.5712
HSPG2 1382 0.361 0.5793
LAMC1 1600 0.332 0.5799
ITGA1 1713 0.319 0.5855
SV2B 1770 0.313 0.5938
TNR 1793 0.31 0.6038
COL1A1 1813 0.307 0.6138
COL3A1 1995 0.285 0.6146
LAMA2 2304 0.257 0.6076
THBS3 2416 0.248 0.6107
RELN 2423 0.248 0.6193
CD44 2458 0.245 0.6264
IBSP 2731 0.225 0.6202
TNN 2747 0.225 0.6275

3.3. RNA and Protein Interaction Analysis

lncRNA-mRNA interaction analysis by lncRRIsearch database revealed that THBS2 has significant interaction with LINC01215, lncRNA TSIX, and lncRNA BAIAP2-AS1. lncRRIsearch finds physical interaction of lncRNAs and mRNAs. Based on this result, three mentioned lncRNAs could regulate the activity and expression level of THBS2 through physical interaction with mRNA THBS2. Also, miRNA interaction analysis revealed that THBS2 has a significant interaction with miR-4677-5p (score (binding probability): 1, energy: -22.5, Figure 5). Based on this information, miR-4677-5p could suppress the expression level of THBS2 through direct interaction with the 3′UTR region of mRNA THBS2. Protein-protein interaction analysis revealed that THBS2 protein has significant protein interaction with following proteins: ADAMTS1, ADAMTS12, ADAMTS2, ADAMTS5, ADAMTSL1, B3GALTL, CD47, ITGB1, LRP1, and MMP2 (Figure 6).

Figure 5.

Figure 5

miRNA and lncRNA interaction analysis of THBS2. Based on the miRWalk database, miRNA interaction analysis was performed. miR-4677-5p has the strongest interaction with the 3′UTR area of THBS2. In addition, lncRNAs LINC01215, TSIX, and BAIAP2-AS1 have direct interaction with THBS2 mRNA, based on the lncRNA interaction analysis using lncRRIsearch database. However, there is no interaction between miRNAs and lncRNAs in this network.

Figure 6.

Figure 6

Protein-protein interaction analysis of THBS2 by STRING online database.

3.4. GO and Pathway Enrichment Analyses

Pathway enrichment and GO analyses were performed on mentioned proteins to find the biological processes, molecular functions, and cellular component, related to THBS2 and its interactome. Based on mentioned analyses, THBS2 and its interactome are located in collagen-containing extracellular matrix (GO:0062023). Also, mentioned proteins (Figure 6) mostly regulate metalloendopeptidase activity (GO:0004222). Furthermore, mentioned genes are significantly involved in extracellular structure organization (GO:0043062) process (Table 5). Pathway enrichment analysis revealed that THBS2 is significantly regulated following signaling pathways: ECM-receptor interaction, malaria, leukocyte transendothelial migration, phagosome, focal adhesion, and proteoglycans in cancer (Table 6).

Table 5.

Gene ontology analysis of THBS2 and related proteins, based on enrichr database.

Gene ontology
Term Adjusted p value Genes
Cellular component
Collagen-containing extracellular matrix (GO:0062023) 0.028067617 ADAMTS1, MMP2, THBS2

Molecular function
Metalloendopeptidase activity (GO:0004222) 4.30E‐11 ADAMTSL1, ADAMTS5, ADAMTS2, ADAMTS1, MMP2, ADAMTS12
Metallopeptidase activity (GO:0008237) 2.34E‐10 ADAMTSL1, ADAMTS5, ADAMTS2, ADAMTS1, MMP2, ADAMTS12
Endopeptidase activity (GO:0004175) 5.03E‐08 ADAMTSL1, ADAMTS5, ADAMTS2, ADAMTS1, MMP2, ADAMTS12
C-X3-C chemokine binding (GO:0019960) 0.013186586 ITGB1
Collagen binding involved in cell-matrix adhesion (GO:0098639) 0.013186586 ITGB1
Cell-matrix adhesion mediator activity (GO:0098634) 0.015376688 ITGB1
Clathrin heavy chain binding (GO:0032050) 0.016462703 LRP1
Protein binding involved in heterotypic cell-cell adhesion (GO:0086080) 0.016462703 CD47
Cell adhesion mediator activity (GO:0098631) 0.034997935 CD47
Lipoprotein particle receptor binding (GO:0070325) 0.036711163 LRP1
Chemokine binding (GO:0019956) 0.038103413 ITGB1
Cell-cell adhesion mediator activity (GO:0098632) 0.045728931 CD47

Biological process
Extracellular structure organization (GO:0043062) 3.00E‐12 ITGB1, ADAMTSL1, ADAMTS5, ADAMTS2, ADAMTS1, MMP2, CD47, ADAMTS12
External encapsulating structure organization (GO:0045229) 3.00E‐12 ITGB1, ADAMTSL1, ADAMTS5, ADAMTS2, ADAMTS1, MMP2, CD47, ADAMTS12
Extracellular matrix organization (GO:0030198) 2.74E‐11 ITGB1, ADAMTSL1, ADAMTS5, ADAMTS2, ADAMTS1, MMP2, CD47, ADAMTS12
Integrin-mediated signaling pathway (GO:0007229) 4.54E‐04 ITGB1, ADAMTS1, CD47
Positive regulation of vascular-associated smooth muscle cell proliferation (GO:1904707) 0.002549534 ADAMTS1, MMP2
Cellular response to cytokine stimulus (GO:0071345) 0.003555608 ITGB1, MMP2, CD47, ADAMTS12
Regulation of angiogenesis (GO:0045765) 0.005029385 ITGB1, ADAMTS1, THBS2
Regulation of vascular-associated smooth muscle cell proliferation (GO:1904705) 0.005029385 ADAMTS1, MMP2

Table 6.

Pathway enrichment analysis of THBS2 and correlated proteins.

Term Adjusted p value Genes
ECM-receptor interaction 4.63E‐04 ITGB1, CD47, THBS2
Malaria 0.005811118 LRP1, THBS2
Leukocyte transendothelial migration 0.019982511 ITGB1, MMP2
Phagosome 0.02639964 ITGB1, THBS2
Focal adhesion 0.031562049 ITGB1, THBS2
Proteoglycans in cancer 0.031562049 ITGB1, MMP2

3.5. Coexpression Analysis of THBS2 with lncRNAs

Coexpression analysis of THBS2 and lncRNAs with ENCORI revealed that THBS2 has no significant coexpression with lncRNA BAIAP2-AS1 (r: 0.063, p value: 2.23E‐01), LINC01215 (r: 0.000, p value: 9.94E‐01), and TSIX (r: -0.046, p value: 3.76E‐01). However, same analyses by GEPIA2 revealed that THBS2 expression has a significant slight positive correlation with BAIAP2-AS1 (r: 0.11, p value: 0.03, Figure 7). However, due to the low r-value of this correlation, demonstrated correlation result needs more validations.

Figure 7.

Figure 7

Coexpression analysis of THBS2 and lncRNAs, based on ENCORI and GEPIA2 online databases. (a) Coexpression analysis based on ENCORI revealed that THBS2 has no significant coexpression with BAIAP-AS1, TSIX, and LINC01215. (b) Coexpression analysis based on GEPIA2 revealed that THBS2 has a significant coexpression with BAIAP2-AS1.

3.6. THBS2 and lncRNAs Have Significant Upregulation in the GC Samples

Expression analysis of THBS2 and selected lncRNAs was performed by GEPIA2 and ENCORI online databases. Based on mentioned analyses, THBS2 (FC: 7.14, FDR < 0.0001), BAIAP2-AS1 (FC: 1.44, FDR: 0.018), TSIX (FC: 1.34, FDR: 0.038), and LINC01215 (FC: 1.19, FDR: 0.046) have significant upregulation in GC samples, compared to control (Figures 8 and 9). Furthermore, survival analysis revealed that high expression of THBS2, LINC01215, TSIX, and BAIAP2-AS1 has a nonsignificant correlation with low survival rate of GC patients (HR: 0.28, logrank p: 0.28, Figure 10).

Figure 8.

Figure 8

Relative expression analysis of THBS2 and selected lncRNAs, based on ENCORI online database. Based on expression analysis by ENCORI, THBS2, LINC01215, BAIAP2-AS1, and TSIX have significant high expression in GC samples, compared to control.

Figure 9.

Figure 9

Relative expression analysis of THBS2 (a), TSIX (b), LINC01215 (c), and BAIAP2-AS1 (d). Based on GEPIA2 online database, THBS2 has a significant high expression in GC samples. Based on this database, LINC01215, BAIAP2-AS1, and TSIX have no significant change in the GC samples.

Figure 10.

Figure 10

Survival analysis of THBS2, BAIAP2-AS1, LINC01215, and TSIX. Based on this analysis, mentioned RNAs have no significant correlation with the low survival rate of GC patients. This analysis was performed using GEPIA2 online database, and the statistical parameter was based on the default setting of this database.

3.7. qRT-PCR Data Analysis

For the validation of mentioned results, qRT-PCR experiment was performed. Based on mentioned analysis, THBS2 (logFC: 1.719, p value: 0.0033), BAIAP2-AS1 (logFC: 3.495, p value: 0.0422), TSIX (logFC: 2.821, p value: 0.0039), and LINC01215 (logFC: 3.119, p value: 0.0014) have significant high expression in human GC samples, compared to control (Figure 11). Based on the Spearman correlation analysis, THBS2 has significant positive coexpression with LINC01215 (r: 0.5576, p value: 0.0038), TSIX (r: 0.5030, p value: 0.0104), and BAIAP2-AS1 (r: 0.6227, p value: 0.0009, Figure 12). ROC analysis revealed that BAIAP2-AS1 (AUC: 0.7136, p value: 0.0096), TSIX (AUC: 0.7456, p value: 0.0029), and LINC01215 (AUC: 0.7872, p value: 0.0005) could be acceptable diagnostic biomarkers of GC (Figure 13).

Figure 11.

Figure 11

qRT-PCR data analysis was performed using GraphPad Prism software. All statistical tests and graphs of qRT-PCR experiment were performed and visualized using that software. Relative expression analysis of qRT-PCR data revealed that THBS2, BAIAP2-AS1, TSIX, and LINC01215 have significant upregulation in GC samples, compared to control.

Figure 12.

Figure 12

Spearman correlation analysis was performed using GraphPad Prism. Spearman correlation analysis revealed that THBS2 has significant positive coexpression with lncRNAs BAIAP2-AS1, LINC01215, and TSIX.

Figure 13.

Figure 13

ROC analysis revealed that BAIAP2-AS1, LINC01215, and TSIX could be considered as the potential diagnostic biomarkers of gastric cancer.

4. Discussion

Our study demonstrates comprehensive novel results about the possible roles of coding and noncoding RNAs in GC development. Based on our investigation, lncRNAs BAIAP2-AS1, LINC01215, and TSIX could be considered novel potential diagnostic biomarkers of GC. Based on our bioinformatics and experimental analyses, mentioned lncRNAs might regulate the expression level of THBS2, a high-expressed mRNA, in GC patients. THBS2 and its interactome regulate the ECM-receptor interaction signaling pathway. Previous studies approved the possible role of the ECM-receptor signaling pathway in the regulation of progression, survival rate, and tumorigenesis of GC [28]. Based on our investigation, BAIAP2-AS1, LINC01215, and TSIX might regulate the ECM-receptor signaling pathway via regulation of the THBS2 signaling pathway. There was no previous study about the possible regulatory role of mentioned lncRNAs in the ECM-receptor signaling pathway. High expression of mentioned lncRNAs might disturb normal processes of the ECM-receptor signaling pathway. This disturbance may lead the normal gastric cells to malignancy. Furthermore, based on our analyses, the expression level of THBS2, BAIAP2-AS1, TSIX, and LINC01215 has a nonsignificant negative correlation with the survival rate of GC patients. ROC analysis revealed that BAIAP2-AS1, LINC01215, and TSIX could have a significant role as potential diagnostic biomarkers of GC.

Furthermore, we demonstrate that the expression level of THBS2 has a significant positive correlation with the expression of BAIAP2-AS1, TSIX, and LINC01215, based on the qRT-PCR experiment. This result could validate our bioinformatics coexpression analyses. Also, based on our bioinformatics analyses, miR-4677-5p has a potential interaction with THBS2 mRNA. Low expression of THBS2 via miR-4677-5p could be considered a potential therapeutic method for GC patients.

Previous studies demonstrated possible roles of noncoding RNAs in different patients, including multiple sclerosis [29], breast cancer [30, 31], and gastric cancer [32]. Previous studies revealed some novel information about the possible roles of BAIAP2-AS1 in different cancer types. For example, Yang et al. in 2021 revealed that BAIAP2-AS1 might have a regulatory role in the miR-361-3p/SOX4 competitive endogenous RNA (ceRNA) axis. Based on this study, mentioned ceRNA axis could regulate the malignant progression of hepatocellular carcinoma (HCC). The mentioned study suggests that BAIAP2-AS1 has a significantly high expression in HCC samples in the TCGA RNAseq datasets, qRT-PCR experiment, and HCC cell lines [33]. Mao et al. in 2018 revealed that BAIAP2-AS1 could have a significant role in the prediction of cervical cancer survival. In the mentioned study, a high-throughput TCGA data analysis was performed to evaluate the expression level of lncRNAs and the relation of selected DEGs with the survival rate of cervical cancer patients. Based on ROC analysis, BAIAP2-AS1 could act as a diagnostic biomarker of cervical cancer [34]. Gong et al. in 2016 revealed that BAIAP2-AS1 has a significant upregulation in the hepatitis B virus-related HCC. Also, by silencing BAIAP2-AS1 (using small interfering RNAs (siRNAs)), it is demonstrated that BAIAP2-AS1 has a significant role in the regulation of MAPKAP1 and RAF1, and this lncRNA could act as a ceRNA in the HCC patients [35]. There was no study about the possible role of BAIAP2-AS1 in GC, and we performed this study of BAIAP2-AS1 for the first time.

Previous studies revealed the possible roles of LINC01215 in the progression of different cancers. For example, according to Liu et al. in 2020, LINC01215 has a significant role in the survival rate of breast cancer patients (HR: 0.84, p value: 0.0001). Furthermore, based on the mentioned study, LINC01215 has a significant association with immune-related functions (the result of the Pearson correlation method) [36]. Liu et al. in 2021 revealed that LINC01215 could promote lymph node metastasis and epithelial-mesenchymal transition in ovarian cancer. Based on this study, the downregulation of LINC01215 increases the expression level of RUNX3 through methylation of the RUNX3 promoter [37].

Furthermore, the downregulation of LINC01215 suppresses tumor growth, migration, and cell proliferation of ovarian cancer [37]. Xu et al. in 2020 revealed that LINC01215 suppresses the growth of clear cell renal cell carcinoma tumors through reducing SLC2A3 expression level via miR-184 [38]. There was no previous study about the possible role of LINC01215 in the development of gastric cancer. About the possible role of lncRNA TSIX in the development of GC, Sun et al. in 2021 revealed that TSIX might regulate the GC development via miR-320a/RAD51 ceRNA axis. Furthermore, this study revealed that the low expression of TSIX is one of the possible causes of RAD51 downregulation in the mentioned ceRNA axis. This ceRNA network simultaneously triggered the ATF6 signaling pathway following endoplasmic reticulum stress to encourage the death of GC cells and stop the illness. The TSIX/miR-320a/Rad51 network offers a novel method for treating GAC disease and may be a possible biological target of the GC [39].

Our study demonstrates comprehensive novel results about the possible roles of different coding and noncoding RNAs in GC development. Based on our investigation, lncRNAs BAIAP2-AS1, LINC01215, and TSIX could be considered novel potential diagnostic biomarkers of GC. Based on our bioinformatics and experimental analyses, mentioned lncRNAs might regulate the expression level of THBS2, a high-expressed mRNA, in GC patients. THBS2 and its interactome regulate the ECM-receptor interaction signaling pathway. Previous studies approved the possible role of the ECM-receptor signaling pathway in the regulation of progression, survival rate, and tumorigenesis of GC [28].

In our study, we introduced a potential signature model for gastric cancer survival prediction, including THBS2, BAIAP2-AS1, LINC01215, and TSIX. However, our result was not statistically significant. Based on the obtained gene score, we suggest that same investigation through different methods be evaluated on our 4 evaluated genes. Previous studies revealed some potential signature models in GC. For example, Cheong et al. at 2020 demonstrated a predictive 32-gene signature model for GC using a predictive model based on support vector machine (SVM) [40]. Another study at 2023 found a 7-gene signature model including the following genes: CCDC91, DYNC1I1, FAM83D, LBH, SLITRK5, WTIP, and NAP1L3. Through a similar approach to our investigation, they demonstrated that their suggested signature model modulated the TGF-beta signaling pathway [41]. Zhang et al. at 2021 introduced a 4-gene prognostic model for GC through a multivariable Cox regression analysis. Based on this article, the following four genes could have potential implications for the prediction of GC: UTRN, MUC16, CCDC178, and HYDIN [42]. However, there is no certain prediction model for GC, and more studies and validations are needed. It is highly recommended that the expression level of miR-4677-5p be evaluated by different experimental methods, like qRT-PCR. lncRNA-mRNA and miRNA-mRNA interactions in this study should be validated using different methods, like luciferase assay. A possible correlation of SNPs in the THBS2 sequence with the binding affinity of miR-4677-5p might be a perfect method to find more accurate information about the reasons for the high or low expression of THBS2. Since the result of our survival analysis was not significant, we highly recommend that the possible correlation of mentioned RNAs with the survival rate of GC patients be evaluated through a bigger sample size.

5. Conclusion

In this study, we demonstrate that upregulation of THBS2, lncRNAs BAIAP2-AS1, LINC01215, and TSIX has a significant correlation with GC. Furthermore, for the first time, we show that lncRNAs BAIAP2-AS1, LINC01215, TSIX, and miR-4677-5p might regulate the expression level of THBS2, and any disturbance in this regulatory network might disturb the ECM-receptor interaction signaling pathway and lead the normal gastric cells to malignancy. Mentioned lncRNAs could be considered as the potential diagnostic biomarkers of GC. Also, the expression level of THBS2, lncRNAs BAIAP2-AS1, LINC01215, and TSIX might have a meaningful negative correlation with the survival rate of GC patients.

Data Availability

The datasets generated or analyzed during the current study are available in the GEO repository, GSE54129.

Ethical Approval

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Ethics Committee of Isfahan University of Medical Sciences.

Consent

Informed consent was obtained from all individual participants included in the study.

Disclosure

A preprint has previously been published [39].

Conflicts of Interest

The authors declare that they have no competing interests.

Authors' Contributions

Benyamin Mashhadi, Naeimeh Parsapour, Ali Barani, and Kamyar Beikverdi have equally contributed to this study as the first authors. Mohammad Rezaei and Pegah Javid have equally contributed to this study as the second authors and supervisors of this project.

References

  • 1.Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: a Cancer Journal for Clinicians . 2011;61(2):69–90. doi: 10.3322/caac.20107. [DOI] [PubMed] [Google Scholar]
  • 2.Wagner A. D., Syn N. L. X., Moehler M., et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews. . 2017;8(8) doi: 10.1002/14651858.CD004064.pub4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Tsimberidou A. M. Targeted therapy in cancer. Cancer Chemotherapy and Pharmacology . 2015;76(6):1113–1132. doi: 10.1007/s00280-015-2861-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Fattahi S., Kosari-Monfared M., Golpour M., et al. LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: a novel approach to personalized medicine. Journal of Cellular Physiology . 2020;235(4):3189–3206. doi: 10.1002/jcp.29260. [DOI] [PubMed] [Google Scholar]
  • 5.Fan B., Shen C., Wu M., Zhao J., Guo Q., Luo Y. miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: a preliminary study. Medicine . 2018;97(35, article e12007) doi: 10.1097/MD.0000000000012007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Guo Y., Yue P., Wang Y., Chen G., Li Y. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis. Biomedicine & Pharmacotherapy . 2019;118, article 109255 doi: 10.1016/j.biopha.2019.109255. [DOI] [PubMed] [Google Scholar]
  • 7.Donyavi M. H., Salehi-Mazandarani S., Nikpour P. Comprehensive competitive endogenous RNA network analysis reveals EZH2-related axes and prognostic biomarkers in hepatocellular carcinoma. Iranian Journal of Basic Medical Sciences . 2022;25(3):286–294. doi: 10.22038/IJBMS.2022.61570.13623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Xu Y. D., Shang J., Li M., Zhang Y. Y. LncRNA DANCR accelerates the development of multidrug resistance of gastric cancer. European Review for Medical and Pharmacological Sciences . 2019;23(7):2794–2802. doi: 10.26355/eurrev_201904_17554. [DOI] [PubMed] [Google Scholar]
  • 9.Li M., Zhang Y. Y., Shang J., Xu Y. D. LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis. European Review for Medical and Pharmacological Sciences . 2019;23(10):4185–4191. doi: 10.26355/eurrev_201905_17921. [DOI] [PubMed] [Google Scholar]
  • 10.Wu X. G., Zhou C. F., Zhang Y. M., et al. Cancer-derived exosomal miR-221-3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma. Angiogenesis . 2019;22(3):397–410. doi: 10.1007/s10456-019-09665-1. [DOI] [PubMed] [Google Scholar]
  • 11.Zhang S., Yang H., Xiang X., Liu L., Huang H., Tang G. THBS2 is closely related to the poor prognosis and immune cell infiltration of gastric cancer. Frontiers in Genetics . 2022;13, article 803460 doi: 10.3389/fgene.2022.803460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gautier L., Cope L., Bolstad B. M., Irizarry R. A. affy—analysis of Affymetrix gene chip data at the probe level. Bioinformatics . 2004;20(3):307–315. doi: 10.1093/bioinformatics/btg405. [DOI] [PubMed] [Google Scholar]
  • 13.Ritchie M. E., Phipson B., Wu D., et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research . 2015;43(7):e47–e47. doi: 10.1093/nar/gkv007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wickham H. Elegant Graphics for Data Analysis . Springer; 2016. ggplot2; pp. 189–201. [DOI] [Google Scholar]
  • 15.Subramanian A., Tamayo P., Mootha V. K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America . 2005;102(43):15545–15550. doi: 10.1073/pnas.0506580102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wójcik A. M. Research tools for the functional genomics of plant miRNAs during zygotic and somatic embryogenesis. International Journal of Molecular Sciences . 2020;21(14):p. 4969. doi: 10.3390/ijms21144969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Tang Z., Kang B., Li C., Chen T., Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Research . 2019;47(W1):W556–W560. doi: 10.1093/nar/gkz430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Otasek D., Morris J. H., Bouças J., Pico A. R., Demchak B. Cytoscape Automation: empowering workflow-based network analysis. Genome Biology . 2019;20(1) doi: 10.1186/s13059-019-1758-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Shannon P., Markiel A., Ozier O., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research . 2003;13(11):2498–2504. doi: 10.1101/gr.1239303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jensen L. J., Kuhn M., Stark M., et al. STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Research . 2009;37(Database):D412–D416. doi: 10.1093/nar/gkn760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Xie Z., Bailey A., Kuleshov M. V., et al. Gene set knowledge discovery with Enrichr. Current Protocols . 2021;1(3, article e90) doi: 10.1002/cpz1.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kuleshov M. V., Jones M. R., Rouillard A. D., et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Research . 2016;44(W1):W90–W97. doi: 10.1093/nar/gkw377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Chen E. Y., Tan C. M., Kou Y., et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics . 2013;14(1) doi: 10.1186/1471-2105-14-128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Dweep H., Sticht C., Pandey P., Gretz N. miRWalk--database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. Journal of Biomedical Informatics . 2011;44(5):839–847. doi: 10.1016/j.jbi.2011.05.002. [DOI] [PubMed] [Google Scholar]
  • 25.Dweep H., Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nature Methods . 2015;12(8):p. 697. doi: 10.1038/nmeth.3485. [DOI] [PubMed] [Google Scholar]
  • 26.Sticht C., De La Torre C., Parveen A., Gretz N. miRWalk: an online resource for prediction of microRNA binding sites. PLoS One . 2018;13(10, article e0206239) doi: 10.1371/journal.pone.0206239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Livak K. J., Schmittgen T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods . 2001;25(4):402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 28.Yang X., Chen L., Mao Y., Hu Z., He M. Progressive and prognostic performance of an extracellular matrix-receptor interaction signature in gastric cancer. Disease Markers . 2020;2020:23. doi: 10.1155/2020/8816070.8816070 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Moradi A., Rahimi Naiini M., Yazdanpanahi N., et al. Evaluation of the expression levels of three long non-coding RNAs in multiple sclerosis. Cell Journal . 2020;22(2):165–170. doi: 10.22074/cellj.2020.6555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zhang Y., Li Y., Wang Q., et al. Identification of an lncRNA-miRNA-mRNA interaction mechanism in breast cancer based on bioinformatic analysis. Molecular Medicine Reports . 2017;16(4):5113–5120. doi: 10.3892/mmr.2017.7304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Warburton A. J., Boone D. N. Insights from global analyses of long noncoding RNAs in breast cancer. Current Pathobiology Reports . 2017;5(1):23–34. doi: 10.1007/s40139-017-0122-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Gharazi H., Tabatabaeian H., Ghaedi K., Houshmand M., Azadeh M. Positive association of rs1049694 allele G located in NDRG1 with the incidence of gastric cancer and metastasis. Gene Reports . 2020;19, article 100646 doi: 10.1016/j.genrep.2020.100646. [DOI] [Google Scholar]
  • 33.Yang Y., Ge H., Li D. Q., Xu A. X. E2F1-induced lncRNA BAIAP2-AS1 overexpression contributes to the malignant progression of hepatocellular carcinoma via miR-361-3p/SOX4 Axis. Disease Markers . 2021;2021:18. doi: 10.1155/2021/6256369.6256369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Mao X., Qin X., Li L., et al. A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma. Gynecologic Oncology . 2018;149(1):181–187. doi: 10.1016/j.ygyno.2017.12.011. [DOI] [PubMed] [Google Scholar]
  • 35.Gong X., Wei W., Chen L., Xia Z., Yu C. Comprehensive analysis of long non-coding RNA expression profiles in hepatitis B virus-related hepatocellular carcinoma. Oncotarget . 2016;7(27):42422–42430. doi: 10.18632/oncotarget.9880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Liu Z., Mi M., Li X., Zheng X., Wu G., Zhang L. A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer. Journal of Cellular and Molecular Medicine . 2020;24(21):12444–12456. doi: 10.1111/jcmm.15762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Liu W., Tan S., Bai X., Ma S., Chen X. Long non-coding RNA LINC01215 promotes epithelial-mesenchymal transition and lymph node metastasis in epithelial ovarian cancer through RUNX3 promoter methylation. Translational Oncology . 2021;14(8, article 101135) doi: 10.1016/j.tranon.2021.101135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Xu H., Wang X., Wu J., et al. Long non-coding RNA LINC01094 promotes the development of clear cell renal cell carcinoma by upregulating SLC2A3 via microRNA-184. Frontiers in Genetics . 2020;11:p. 11. doi: 10.3389/fgene.2020.562967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Sun Z., He Z., Liu R., Zhang Z. Cation lipid-assisted PEG6-PLGA polymer nanoparticles encapsulated knocking down long ncRNAs reverse non-coding RNA of Xist through the support vector machine model to regulate the molecular mechanisms of gastric cancer cell apoptosis. Journal of Biomedical Nanotechnology . 2021;17(7):1305–1319. doi: 10.1166/jbn.2021.3107. [DOI] [PubMed] [Google Scholar]
  • 40.Cheong J. H., Wang S. C., Park S., et al. Development and validation of a prognostic and predictive 32-gene signature for gastric cancer. Nature Communications . 2022;13(1) doi: 10.1038/s41467-022-28437-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Velásquez Sotomayor M. B., Campos Segura A. V., Asurza Montalva R. J., Marín-Sánchez O., Murillo Carrasco A. G., Ortiz Rojas C. A. Establishment of a 7-gene expression panel to improve the prognosis classification of gastric cancer patients. Frontiers in Genetics . 2023;14 doi: 10.3389/fgene.2023.1206609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Zhang B., Li Y., Yang L., Chen Y. A four-gene-based risk score with high prognostic value in gastric cancer. Frontiers in Oncology . 2021;11 doi: 10.3389/fonc.2021.584213. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets generated or analyzed during the current study are available in the GEO repository, GSE54129.


Articles from International Journal of Genomics are provided here courtesy of Wiley

RESOURCES